Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
Xencor, Inc.
Xencor, Inc.
University of Washington
Exelixis
Valerio Therapeutics
Eli Lilly and Company
Canadian Cancer Trials Group
Xencor, Inc.
Corcept Therapeutics
MacroGenics
Gilead Sciences
Abramson Cancer Center at Penn Medicine
Swiss Cancer Institute
University of Washington
Alliance for Clinical Trials in Oncology
Pfizer
Albert Einstein College of Medicine
University of Chicago
Wake Forest University Health Sciences
Ohio State University Comprehensive Cancer Center
University of Washington
Wake Forest University Health Sciences
Wake Forest University Health Sciences
Fred Hutchinson Cancer Center
OHSU Knight Cancer Institute
University of Louisville
Fred Hutchinson Cancer Center
University of Southern California
Cancer Research UK
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)
University of Arizona
Ohio State University Comprehensive Cancer Center
City of Hope Medical Center
National Cancer Institute (NCI)
University of Washington
Indiana University
University of Minnesota
Duke University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
INSYS Therapeutics Inc
National Cancer Institute (NCI)
European Organisation for Research and Treatment of Cancer - EORTC
National Cancer Institute (NCI)
Dartmouth-Hitchcock Medical Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
European Organisation for Research and Treatment of Cancer - EORTC
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Kentucky